Trader notes, earnings previews, Confluences, weekly digests and roundups — long-form analysis grounded in ORTEX short interest, options flow and analyst data.
Trader Note — 15397 total
ABI enters the post-earnings period with a striking pattern: a cluster of senior insiders offloaded shares last week at the same time short sellers were quietly rebuilding positions — a combination that deserves more…
CWS — the AdvisorShares Focused Equity ETF — is closing a mixed week down 1.2%, even as a sharp jump in estimated short shares draws attention to an otherwise quiet name. The most notable development this week is a…
Madrigal Pharmaceuticals heads into the post-earnings stretch with short sellers retreating and the Street turning incrementally more constructive — the tension being that even after a 6.4% earnings-day pop, shorts…
Intellia Therapeutics walks into its Q1 2026 earnings report — due after the close on May 14 — carrying the heaviest short positioning it has seen in weeks and a Street that is rapidly repricing what this gene-editing…
Moleculin Biotech enters its May 19 earnings report with the borrow market under real pressure — and a short score near the top of the universe. The most striking development this week is how rapidly shorts have built.…
Altimmune just reported Q1 results, beat its EPS estimate, and simultaneously saw short sellers add aggressively — a setup that puts the stock in a genuinely unusual position heading into what comes next. The short…
Block, Inc. enters the week after its strongest post-earnings session in recent memory, yet the analyst response has been broadly cautious: targets lifted, ratings held. That tension — strong execution against a…
Hewlett Packard Enterprise arrives at its June 1 earnings date with a striking split: short sellers have pulled back sharply from April's highs, yet the options market just flashed its most defensive reading of the…
XLRE enters the week with an unusual split: the price is rising, yet the options market is flashing its most defensive reading in months. The options story is the most striking data point this week. Put demand has…
PYPL closes out the week before its May 19 earnings call in an awkward spot: down 2.3% on the week at $45.44, sitting 13% below the Street's mean price target, and absorbing a fresh batch of analyst cuts in the days…
Ollie's Bargain Outlet heads into its June 3 earnings date with the stock down sharply, the Street paring back targets, and options traders unusually bullish — a combination that makes the setup worth watching…
BRSL enters the post-earnings period under real pressure. A Q1 miss, a fresh 12-month low, and a month-long build in short interest have converged in a single ugly week. The catalyst was Tuesday's earnings release.…
STERIS plc posted a sharp 4.5% single-session gain on May 12 — its fiscal Q4 earnings day — yet the stock remains nearly 1% lower on the week and down 17% year-to-date. The tension between a solid earnings beat and a…
FRPH just delivered its Q1 2026 earnings, and the headline numbers were soft. What stands out more is who put $10 million of their own money into the stock — and exactly when they did it. Chairman John Baker II…
Corbus Pharmaceuticals just delivered a notable week: Q1 earnings arrived, the stock rallied more than 7%, and every analyst on the name trimmed their target anyway. That tension — a price climbing while Street…
GoPro reported Q1 earnings on May 11 and missed by $0.32 per share. The stock fell 17.5% on the day. Then, on Wednesday, came a twist: the company retained Houlihan Lokey as a financial adviser to explore a potential…
Syndax Pharmaceuticals enters the back half of May with one of the highest short burdens in small-cap biotech — yet the analysts covering it remain uniformly bullish, pointing to a gap between positioning and…
JD.com enters the post-earnings spotlight with a familiar tension at its core: revenue growth that impresses the Street, and a profit line that does the opposite. The company reported Q1 2026 results on May 12, with…
ATYR is the week's most dramatic biotech wreckage — a 44% single-day collapse that leaves the stock at $0.53, down 37% on the week and 36% over the past month. The trigger was blunt. On May 11, aTyr Pharma announced a…
IBP entered this week in freefall — down 28% over five days to $202.65 — yet company insiders were buying aggressively into the dip, creating the week's sharpest tension in the name. The trigger was last week's…
